Management outlined a revised UK submission strategy and early named patient access plans for Ebstracel.
Why Is INmune Bio Inc. (INMB) Stock Down Today?
Updated Nov 19, 2026 6:53 PM ET · Prev Close $1.03
Session Regime & Catalyst Assessment
68% Signal ConvictionINmune Bio Inc. Pulling Back 13.19% on 1.17x Relative Volume
INmune Bio Inc. (INMB) is pulling back 13.19% (-$0.14) to $0.89 on 1.17x average session volume. Relative to benchmarks, INMB is lagging the S&P 500 by -11.23%. 14-day RSI stands at 23.4, keeping momentum in a oversold regime.
Management outlined a revised UK submission strategy and early named patient access plans for Ebstracel.
Price ($0.89) trades relative to 20-day SMA ($1.23) and 50-day SMA ($1.64).
Market & Sector Relative Strength
INMB lagging the S&P 500 by -11.23%Options Flow & Execution Desk
Unlock 1 Strike-Verified Options Setup for INMB
Our options desk modeled ATM Call Rebound / Continuation structures for the Dec 18 expiration cycle, plus live unusual contract strike sweeps and full factor sub-scores.
Recent INMB Catalyst Headlines
Verified WireMoby summary of INmune Bio, Inc.'s Q3 2026 earnings call
INmune Bio Inc INMB targets a February 2027 UK marketing application and mid-2027 approval for Ebstracell while funding operations only through Q3 2027.
Company Advances Ebstrocel Toward Potential UK Approval Company to Host Conference Call on November 5, 2026, at 4 30pm Et Boca Raton, Fla., Nov. 05, 2026 Globe Newswire -- inmune Bio Inc. Nasdaq Inmb the Company , a late
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.89 (session support) for directional breakout confirmation.
Technical Regime (INMB)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishBearish sentiment dominates $INMB on StockTwits with no positive news to offset the negative sentiment.
About INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, Xpro1595, LIVNate, and others.
Get Instant INMB Catalyst Alerts
Receive an email alert when INMB triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversINMB Session & Catalyst FAQ
Why is INMB stock down today?
INmune Bio Inc. (INMB) is pulling back 13.19% (-$0.14) to $0.89 on 1.17x average session volume. Relative to benchmarks, INMB is lagging the S&P 500 by -11.23%. 14-day RSI stands at 23.4, keeping momentum in a oversold regime.
Is INMB stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.17x relative volume (moderate participation). Our multi-factor model currently rates INMB as HOLD. Review full valuation, quality, and timing signals on the INMB Buy or Sell Decision Brief →
What is INMB's intrinsic value and expected trading range?
At $0.89, INMB's modeled 1-to-3 session range is $0.84 – $0.94, with a key inflection level at $0.89 (session support). Compare current price against multi-year cash flow projections in the INMB Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for INMB?
RSI at 23.4 indicates oversold conditions — watch for mean-reversion support. INMB trades at $0.89 relative to its 20-day SMA ($1.23) and 50-day SMA ($1.64), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.